Methadone News and Research RSS Feed - Methadone News and Research

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

Total costs of treatment for babies with neonatal abstinence syndrome on the rise

As more infants are born to mothers with dependence on prescription pain medications, the costs of treatment for babies with neonatal abstinence syndrome (NAS) have increased dramatically, suggests a report in the March/April issue of the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D virus (HDV) in that country. [More]
Heroin-assisted treatments benefit some drug users

Heroin-assisted treatments benefit some drug users

Drug users who do not benefit from conventional treatments for heroin addiction should be able to access the drug through the health system, urges a Canadian expert in The BMJ today. [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
Opioid withdrawal in Ontario newborns increases 15-fold

Opioid withdrawal in Ontario newborns increases 15-fold

The number of newborns suffering from opioid withdrawal increased 15-fold in Ontario over 20 years, according to research published today in CMAJ Open. [More]
Use of methadone drug to treat pain increases mortality risk

Use of methadone drug to treat pain increases mortality risk

Outside the hospital, use of methadone to treat pain carries a 46 percent increased risk of death when compared to the equally effective but more costly alternative, morphine SR (sustained release). [More]
New experimental study shows immunotherapy can reduce acute effects of heroin

New experimental study shows immunotherapy can reduce acute effects of heroin

Immunotherapy could have a place in the treatment of substance abuse in the future. A specific antibody can reduce the acute effects of heroin, according to a new experimental study at the Norwegian Institute of Public Health. [More]
European countries implement ATOME project to study improved access to essential painkillers

European countries implement ATOME project to study improved access to essential painkillers

Governments in 12 European countries are to implement the recommendations of research into why more patients are not receiving essential painkillers. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV). [More]
Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Researchers from Rhode Island and The Miriam hospitals and the Stanford University School of Medicine have found that prescription opioids, including methadone, were involved in 67.8 percent of (or over 135,971 visits to) nationwide emergency department (ED) visits in 2010, with the highest proportion of opioid overdoses occurring in the South. [More]
RAND study: Specific state guidance can influence patient access to effective heroin treatment

RAND study: Specific state guidance can influence patient access to effective heroin treatment

State policies can influence the number of physicians licensed to prescribe buprenorphine, a drug that can treat addiction to heroin and other opioids in outpatient settings, according to a new RAND Corporation study. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Low dose of opioids including methadone effective for treatment of testosterone suppression

Low dose of opioids including methadone effective for treatment of testosterone suppression

Treatment for opioid addiction tampers with the testosterone levels of male but not female opioid users, McMaster University research has shown. [More]
Researchers focus on how exposure to opioids may alter expression of OPRM1 gene

Researchers focus on how exposure to opioids may alter expression of OPRM1 gene

Some infants born with neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure have a more difficult time going through withdrawal than others, but the underlying reasons are not well understood. [More]
New therapeutic drug may prevent respiratory depression in patients taking opioid medication

New therapeutic drug may prevent respiratory depression in patients taking opioid medication

People taking prescription opioids to treat moderate to severe pain may be able to breathe a little easier, literally. [More]
Rockefeller scientists identify protein that makes breast cancer cells more likely to metastasize

Rockefeller scientists identify protein that makes breast cancer cells more likely to metastasize

Using an innovative tool that captures heretofore hidden ways that cells are regulated, scientists at Rockefeller University have identified a protein that makes breast cancer cells more likely to metastasize. [More]
Advertisement
Advertisement